Vor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 1,400 Shares

Vor Biopharma Inc. (NYSE:VOR) major shareholder Reprogrammed Interchange Llc sold 1,400 shares of the company’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $39.19, for a total value of $54,866.00. Following the completion of the transaction, the insider owned 1,637,660 shares in the company, valued at $64,179,895.40. This represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The stock was sold at an average price of $37.83, for a total value of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total value of $1,292,523.33.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total value of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.80, for a total value of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total value of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The stock was sold at an average price of $35.00, for a total value of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The stock was sold at an average price of $36.60, for a total value of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The stock was sold at an average price of $39.80, for a total value of $924,195.80.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 17,500 shares of Vor Biopharma stock. The stock was sold at an average price of $36.40, for a total value of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 22,461 shares of Vor Biopharma stock. The stock was sold at an average price of $40.00, for a total value of $898,440.00.

Vor Biopharma Trading Up 2.1%

VOR opened at $37.46 on Friday. The stock has a 50-day moving average price of $38.88 and a 200-day moving average price of $24.15. Vor Biopharma Inc. has a 12-month low of $2.62 and a 12-month high of $65.80. The stock has a market capitalization of $256.75 million, a P/E ratio of -22.70 and a beta of 2.05.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the business. Money Concepts Capital Corp lifted its holdings in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after buying an additional 26,535 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after buying an additional 58,247 shares during the period. XTX Topco Ltd purchased a new stake in Vor Biopharma in the 2nd quarter worth approximately $66,000. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma in the 1st quarter worth approximately $100,000. Finally, Jane Street Group LLC purchased a new stake in Vor Biopharma in the 1st quarter worth approximately $140,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on VOR shares. Stifel Nicolaus upgraded Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a report on Wednesday, September 24th. Wedbush restated an “outperform” rating on shares of Vor Biopharma in a report on Thursday, June 26th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Vor Biopharma in a report on Thursday, August 14th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $113.83.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.